Program
PG4 Multivalent Vaccine
Its studies are mostly in Pneumococcal Infections, led by Pfizer.
Furthest: phase 3, since Aug 26, 20261 company-led study, 1 open or runningNext primary completion: Apr 26, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 11 open or running | phase 3since Aug 26, 2026 | Aug 26, 2026 | Apr 26, 2027phase 3 · NCT07794748 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 26, 2026First study: phase 3 study in Pneumococcal InfectionsFirst studyNCT07794748 · 4,701 enrolled · United States
Ahead
- Apr 26, 2027Primary completion: phase 3 study in Pneumococcal InfectionsNCT07794748
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“PG4 Multivalent Vaccine”name, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07794748Pneumococcal Infections · United States | 3 | Active, not recruiting | Apr 26, 2027 | 4,701 |
How it is read
Names in the registry
- “PG4 Multivalent Vaccine”, 3 entries
Conditions, from the studies’ own filings
- Pneumococcal Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.